TY - JOUR
T1 - Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease
AU - Peng, Chiung Chi
AU - Hsieh, Chiu Lan
AU - Wang, Hui Er
AU - Chung, Jin Yuan
AU - Chen, Kuan Chou
AU - Peng, Robert Y.
N1 - Funding Information:
The authors are grateful for financial support from the National Science Council 98-2320-B-038-024, 99-2320-B-038-011-MY3, 97-2320-B-039-049-MY3 & 99-2320-B-039-034 . The authors also acknowledge financial support of CMU97-234 & CMU99-N1-09 from Chinese Medical University .
PY - 2012/6
Y1 - 2012/6
N2 - Backgrounds & aims: The long term therapeutic effect of ferulic acid (FA) and gallic acid (GA) in treatment of chronic kidney disease (CKD) has been lacking. Methods: Doxorubicin (DR, Adriamycin)-induced CKD rat model was established for this study. Results: DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-α, and urinary creatinine and elevated serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, and IL-6. In DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity. The inhibitory effects of FA and GA on MMP-2 were very comparable. GA suppressed MMP-2 more effectively than FA in DRCKD rats. Both FA and GA induced SOD elevation and MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further up-regulated CD34, α-SMA, tissue pDGFR, p-PDGFR, and TGF-β; and down-regulated p-PI3K, and p-Akt. Since both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage, GA was proved to be more beneficial in this regard. Conclusions: GA tends to protect the CKD while FA is not recommended for the long term CKD therapy.
AB - Backgrounds & aims: The long term therapeutic effect of ferulic acid (FA) and gallic acid (GA) in treatment of chronic kidney disease (CKD) has been lacking. Methods: Doxorubicin (DR, Adriamycin)-induced CKD rat model was established for this study. Results: DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-α, and urinary creatinine and elevated serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, and IL-6. In DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity. The inhibitory effects of FA and GA on MMP-2 were very comparable. GA suppressed MMP-2 more effectively than FA in DRCKD rats. Both FA and GA induced SOD elevation and MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further up-regulated CD34, α-SMA, tissue pDGFR, p-PDGFR, and TGF-β; and down-regulated p-PI3K, and p-Akt. Since both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage, GA was proved to be more beneficial in this regard. Conclusions: GA tends to protect the CKD while FA is not recommended for the long term CKD therapy.
KW - Chronic kidney disease
KW - Ferulic acid
KW - Gallic acid
KW - PDGF
KW - α-SMA
UR - http://www.scopus.com/inward/record.url?scp=84861346250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861346250&partnerID=8YFLogxK
U2 - 10.1016/j.clnu.2011.11.003
DO - 10.1016/j.clnu.2011.11.003
M3 - Article
C2 - 22154988
AN - SCOPUS:84861346250
SN - 0261-5614
VL - 31
SP - 405
EP - 414
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 3
ER -